Drug Trial Radar · NCT01904604
Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
Last checked: Nov 19, 2026Latest source record: Jul 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Sep 2013
Primary completion
Aug 2015
Study completion Aug 21, 2018
Sponsor
- Sponsor type
- NIH
- Collaborators
- Consortium of Food Allergy Research
- First posted
- Jul 22, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 4 years, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Food allergy occurs when the immune system reacts against foods. The immune system is the part of the body that protects us from illness and germs, but it can also cause allergies. Peanut allergy occurs in 1 - 2% of people in the United States and other Western countries. There is proof that allergy to peanut is increasing. Allergic reactions to peanut can be severe and life threatening. The only way that you can prevent an allergic reaction is to avoid exposure to peanuts. However, peanut proteins are found in a variety of foods and people can be accidently exposed to peanut proteins. Treatment for accidental exposure include antihistamines (medications like Benadryl), and injectable epinephrine (adrenalin) which must be carried at all times. DBV Technologies has developed an epicutaneous delivery system, a patch that puts the peanut protein on the skin.
Conditions
- Peanut Hypersensitivity
- Food Hypersensitivity
- Hypersensitivity
- Hypersensitivity, Immediate
Interventions
Placebo Viaskin® PatchBiological
Placebo (e.g., no peanut) patch in an epicutaneous application for 24 hours every 24 hours.
Low-dose DBV712 Viaskin® PatchBiological
100 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
High-dose DBV712 Viaskin® PatchBiological
250 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With a Successful Treatment ResponseTime frame: Week 52
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas
National Jewish Health
Denver, Colorado
The Johns Hopkins University
Baltimore, Maryland
Icahn School of Medicine at Mount Sinai
New York, New York
University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.